VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | Current treatment approaches in ET and an insight into the SURPASS-ET trial

Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of current treatment strategies in essential thrombocythemia (ET), and further highlights the Phase III SURPASS-ET trial (NCT04285086), which is comparing anagrelide versus ropeginterferon alfa-2b in patients with ET. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter